Xu et al. demonstrated that SAA1 may serve as a novel marker for predicting the prognosis of ccRCC patients and may also be expressed in the tumor microenvironment (TME) through mast cell resting and PDL1 expression. This evidence concerns the gene CD274 and nonpapillary renal cell carcinoma.